In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ionis Pharmaceuticals Inc.

www.ionispharma.com

Latest From Ionis Pharmaceuticals Inc.

The Eye Travels Wide: ProQR’s Bid For Leadership In The Genetics Of Sight

How did a youthful vendor of IT services, faced with a personal exposure to crippling illness, attract some of the best minds in biotech to launch a company with a then-untested RNA technology that today is a contender for leadership in the rarified space of inherited retinal disease? The answer may lie in the ambitiously definitive name that 36-year-old founder Daniel de Boer gave to his enterprise with a mission: ProQR – an active synonym for finding cures.

C-Suite Speaks Gene Therapy

Deal Watch: Lilly Partners With Avidity On RNA Medicines That Can Target Outside The Liver

Privately held Avidity’s platform creates antibody-oligonucleotide conjugate therapies, which build on RNAi approaches. Basilea/Forge collaboration seeks to create novel antibiotics using metalloenzyme chemistry.

Deals Business Strategies

Biogen Stays Steady As Alzheimer’s Programs Falter

Still reeling from aducanumab’s failure in Phase III Alzheimer’s trial, Biogen management played up the company’s progress toward diversification and the promise of its pipeline. 
Sales & Earnings Biosimilars

Amyloidosis Drug PROs Supported Clinical Meaningfulness Of Objective Measures

In pivotal trials for Alnylam’s Onpattro and Ionis’ Tegsedi, statistically persuasive results on a patient-reported, quality-of-life measure were needed to show the drugs had a meaningful benefit on how hATTR patients with polyneuropathy feel and function, US FDA said.

Drug Review Profile Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cancer
  • Cardiovascular
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Renal System
  • Alias(es)
  • Isis Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ionis Pharmaceuticals Inc.
  • Senior Management
  • Stanley T Crooke, MD, PhD, Chmn. & CEO
    Elizabeth L Hougen, SVP, Fin. & CFO
    C. Frank Bennett, PhD, SVP, Research
    Sanjay Bhanot, MD, PhD, CMO
    Damien McDevitt, PhD, CBO
    Richard S Geary, PhD, SVP, Dev.
  • Contact Info
  • Ionis Pharmaceuticals Inc.
    Phone: (760) 931-9200
    2855 Gazelle Ct.
    Carlsbad, CA 92010
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register